China NMPA Product Recall - SynchroMed II Programmable Drug Infusion System

On March 20, 2013, the National Medical Products Administration (NMPA) announced a recall initiated by Medtronic Inc. for its SynchroMed Programmable Drug Infusion System (SynchroMed II). This recall, reported by Medtronic (Shanghai) on January 14, 2013, impacts products distributed globally, including 24 identified customers in China. The core issue involves a potential for permanent motor failure and an elevated risk of drug infusion termination when unapproved drugs are administered through the system. Data indicated a 7.0% failure rate with unapproved drugs, substantially higher than the 2.4% rate observed with approved medications. Motor gear corrosion was identified as a contributing factor. Medtronic emphasized that treatment failures or changes resulting from these motor issues, particularly with unapproved drugs, could lead to serious injury or death. Under the NMPA's regulatory framework, Medtronic's required actions include informing customers to strictly use only FDA-approved drugs listed for the SynchroMed system. Healthcare providers are explicitly cautioned against using mixed, unapproved drugs, or unapproved formulations to mitigate device malfunction risks and ensure patient safety.